Oxford Asset Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-400,000
| Closed | -$4.46M | – | 2028 |
|
|
2017
Q3 | $4.46M | Hold |
400,000
| – | – | 0.09% | 253 |
|
|
2017
Q2 | $4.4M | Buy |
+400,000
| New | +$4M | 0.09% | 240 |
|
|
2017
Q1 | – | Sell |
-64,127
| Closed | -$693K | – | 1547 |
|
|
2016
Q4 | $693K | Sell |
64,127
-303,673
| -83% | -$3.04M | 0.02% | 540 |
|
|
2016
Q3 | $3.77M | Buy |
367,800
+101,829
| +38% | +$1.11M | 0.12% | 212 |
|
|
2016
Q2 | $3.47M | Sell |
265,971
-47,666
| -15% | -$625K | 0.11% | 238 |
|
|
2016
Q1 | $3.45M | Buy |
313,637
+29,092
| +10% | +$259K | 0.1% | 261 |
|
|
2015
Q4 | $2.62M | Buy |
284,545
+130,279
| +84% | +$1.09M | 0.06% | 339 |
|
|
2015
Q3 | $1.07M | Sell |
154,266
-208,632
| -57% | -$1.79M | 0.03% | 398 |
|
|
2015
Q2 | $3.56M | Sell |
362,898
-64,574
| -15% | -$588K | 0.1% | 232 |
|
|
2015
Q1 | $3.79M | Sell |
427,472
-174,419
| -29% | -$1.39M | 0.1% | 239 |
|
|
2014
Q4 | $5.33M | Sell |
601,891
-109,478
| -15% | -$886K | 0.12% | 190 |
|
|
2014
Q3 | $4.91M | Buy |
+711,369
| New | +$4.26M | 0.11% | 186 |
|
|
2014
Q1 | – | Sell |
-221,369
| Closed | -$1.12M | – | 837 |
|
|
2013
Q4 | $1.12M | Sell |
221,369
-120,767
| -35% | -$581K | 0.03% | 501 |
|
|
2013
Q3 | $1.74M | Buy |
342,136
+259,885
| +316% | +$1.45M | 0.04% | 495 |
|
|
2013
Q2 | $408K | Buy |
+82,251
| New | +$391K | 0.01% | 709 |
|
Oxford Asset Management's SCLN Position: Q4 2017 in Review
Oxford Asset Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 400,000 shares — an estimated $4.46M sold.
Oxford Asset Management first reported a position in SCLN in Q2 2013 and held it in 15 quarters. The position peaked at $5.33M in Q4 2014. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Oxford Asset Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Oxford Asset Management sold 400,000 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $4.46M.
- Oxford Asset Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Oxford Asset Management's Sciclone Pharmaceuticals Inc position peaked at $5.33M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Oxford Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.